Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Drug-Related Side Effects and Adverse Reactions 3Neoplasms 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hematologic Neoplasms 2Brain Neoplasms 2Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pneumonia 1Oropharyngeal Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Hepatectomy 1Down Syndrome 1Cranial Nerve Diseases 1

Interventions

Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acute Gout × Methylprednisolone × 1 year × Clear all
NCT05925166 2026-04-15

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

Jiangxi Provincial People's Hopital

Phase NA Completed
26 enrolled

Acute Gout

Data powered by HemOnc (CC BY 4.0) Colophon âš¡